🟢 Definium Therapeutics is trading 4.47% up in after-hours trading after FDA Breakthrough Therapy designation for DT120 ODT

Definium Therapeutics is trading 4.47% up at $39.94 after the FDA granted Breakthrough Therapy designation to DT120 ODT for major depressive disorder following positive Phase 3 results.

• The designation may accelerate development and regulatory review for the company’s lysergide program.
• The move is notable against a weaker broader market: the S&P 500 was down 0.55% and Nasdaq down 0.44% on September 8, 2026.